NVSEF - Novartis AG

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 103,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vasant Narasimhan	Chief Exec. Officer	5.66M	N/A	1976
Mr. Harry Kirsch	Chief Financial Officer	2.87M	N/A	1965
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1.56M	N/A	1968
Ms. Karen L. Hale	Chief Legal Officer	2.36M	N/A	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	2.12M	N/A	1968
Dr. Steffen Lang Ph.D.	Pres of Operations	2.35M	N/A	1967
Ms. Marie-France Tschudin	Pres of Innovative Medicines International & Chief Commercial Officer	2.4M	N/A	1971
Mr. Victor Bulto	Pres of Innovative Medicines US	2.39M	N/A	N/A
Dr. Shreeram Aradhye M.D.	Pres of Global Drug Devel. & Chief Medical Officer	2.3M	N/A	1963
Mr. Aharon Gal Ph.D.	Chief Strategy & Growth Officer	6.34M	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of June 1, 2023 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.